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Aims: Anal squamous cell carcinomas (ASCC) are strongly associated with human papillomaviruses. Standard of care is chemoradiotherapy at uniform doses
with no treatment stratification. Immunohistochemical staining for p16INK4A (p16), a surrogate for human papillomaviruses, is prognostic for outcomes. We
investigated this alongside clinical-pathological factors, including tumour infiltrating lymphocyte (TIL) scores.
Materials and methods: Using an independent, multicentre cohort of 257 ASCC treated with chemoradiotherapy, pretreatment biopsies were stained and scored
for p16 and TIL. KaplaneMeier curves were derived for outcomes (disease-free survival [DFS], overall survival and cancer-specific survival), by stage, p16 and TIL
scores and Log-rank tests were carried out to investigate prognostic effect. A multivariate analysis was carried out using Cox regression.
Results: Stage, sex, p16 and TILs were independently prognostic. Hazard ratios for death (overall survival) were 2.51 (95% confidence interval 1.36e4.63) for p16
negative versus p16 positive, 2.17 (1.34e3.5) for T3/4 versus T1/2, 2.42 (1.52e3.8) for males versus females and 3.30 (1.52e7.14) for TIL1 versus TIL3 (all P < 0.05).
Conclusions: We have refined prognostic factors in ASCC. p16 adds to stratification by stage with respect to DFS in early disease and overall survival/DFS in
locally advanced cancers. Our data support the role of the host immune response in mediating outcomes. These factors will be prospectively evaluated in PLATO
(ISRCTN88455282).
 2021 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Anal squamous cell carcinomas (ASCC) are relatively rare
but are increasing in incidence [1]. They are strongly asso-
ciated with high-risk subtypes of human papillomaviruses
(HPV) [2] and share biological and clinical features with
other HPV-associated neoplasms [3]. Phase III trialsAuthor for correspondence: D.C. Gilbert, Sussex Cancer Centre, Royal
Sussex County Hospital, Eastern Road, Brighton BN2 5BE, UK.
E-mail address: duncan.gilbert2@nhs.net (D.C. Gilbert).
https://doi.org/10.1016/j.clon.2021.04.015
0936-6555/ 2021 The Authors. Published by Elsevier Ltd on behalf of The Royal
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).determined chemoradiotherapy (CRT) with mitomycin and
5-fluorouracil as the standard of care (although notably
with lower doses of radiotherapy than comparable head
and neck or cervical cancers), replacing radical surgery and
permanent colostomy as primary curative treatment.
Clinical and pathological features that are prognostic for
inferior outcomes following CRT include primary tumour
and lymph node stage, male gender [4], smoking, lack of
concurrent chemotherapy and radiotherapy treatment in-
tensity and compliance [5]. Within these parameters,
however, there exists a spectrum of responses and a majorCollege of Radiologists. This is an open access article under the CC BY-NC-ND
K. Wakeham et al. / Clinical Oncology 33 (2021) 638e649 639opportunity to improve prognostication through better
characterisation of relevant biomarkers [6] and use this to
develop strategies to improve outcomes.
In parallel with oropharyngeal cancer, where HPV
involvement confers a significantly improved prognosis
[7,8], HPV status has been investigated as a prognostic
marker in ASCC. Single institution studies [9e12] show that
HPV involvement or its surrogate e immunohistochemical
staining for p16INK4A e are associated with improved
outcomes and an individual patient data meta-analysis
(eight studies/666 anal cancer patients) facilitated multi-
variate analysis where HPV/p16-positive status remained
prognostic [13]. Specifically, negative p16 immunohisto-
chemistry conferred a hazard ratio for relapse of 2.38 (95%
confidence interval 1.64e3.33). Unlike oropharyngeal can-
cers, however, the vast majority of ASCC are HPV positive
(81% were p16 positive in the meta-analyses), so the clinical
utility of HPV/p16 is limited. Importantly, prior studies have
not investigated the additional prognostic benefit of p16
immunohistochemistry to stage, i.e. in early or locally
advanced disease.
The sensitivity of HPV-associated tumours to CRT may
arise from their wild-type p53 status (p53 mutations are
mutually exclusive with HPV involvement across the HPV-
associated cancers [14]). An alternative is that host immune
recognition (potentially driven by viral neoantigens) modu-
lates the response to CRT and subsequent disease control.
Consistent with this, pretreatment haematological parame-
ters, such as neutrophil/lymphocyte ratios, have been shown
to have prognostic value [15,16], and in previous single-
centre studies a higher degree of tumour infiltrating lym-
phocytes (TIL) appeared to confer a strong beneficial effect
[17,18]. Again, this mirrors the situation in oropharyngeal
cancer, where TIL scores add prognostic value to p16/HPV
status [19]. Specifically, Ward and co-workers [19] showed
that patients with HPV-positive/TIL high tumours had
excellent rates of disease control and survival, whereas HPV-
positive but TIL low cancers conferred outcomes similar to
HPV-negative cases.
In order to better understand the relationship between
these clinical and tissue prognostic biomarkers, both to
guide the analysis of clinical outcomes and frame scientific
questions to determine their predictive value within rand-
omised studies of treatment alteration, we investigated
these factors (immunohistochemistry for p16 and scoring of
TIL) and how they relate to clinical stage groupings and
outcomes in an entirely separate cohort of patients treated
with standard of care CRT from four UK centres.Materials and Methods
Ethics and Data Collection
Ethical approval for this work was granted by the UK Na-
tional Research Ethics Service (15/LO/0603). Data were
retrieved from each institution using a standardised tem-
plate, recording patient sex, T (1e4) and N (1/0) stage at
presentation (patientswithmetastatic diseasewere excludedfrom the study), smoking status, confirmation of completion
of CRT with date and status at point of censor (disease free,
locoregional/metastatic relapse, deathwith cause and date of
death). We followed the recommendations of Simon and co-
workers [20] in the design and conform with the REMARK
guidelines in reporting this study [21].
p16 and Tumour Infiltrating Lymphocyte Scoring
Samples (formalin fixed and paraffin embedded) were
retrieved under anonymous study numbers and reviewed
by specialist pathologists (MW, KS, SB) to confirm the
presence of invasive ASCC.
Slides were cut from a representative block from each
tumour and stained for p16 using the automated Dako
Autostainer Link 48 system. Staining for p16 was carried out
using mouse antihuman monoclonal p16 antibody within
the p16 CINtec Histology V.Kit (mtm laboratories AG, Hei-
delberg, Germany) with cervical cancer specimens as a
positive control. Slides were categorised as p16 positive or
negative by pathologists blinded to clinical outcomes. p16
was considered absent if <5% cells stained positive.
Slides stained with haematoxylin and eosin (H&E) were
used to assess infiltration of lymphocytes into the tumours
[19], scored by pathologists trained on slides from the
previous study [17] and blinded to patient demographics or
outcomes. Using a low-power magnification ( 2.5 objec-
tive), TILs were scored as high (3 e diffuse, present in >80%
tumour/stroma), moderate (2 e patchy, present in 20e80%
tumour/stroma) or low (1 e weak/absent, present in <20%
tumour/stroma).
Statistical Analysis
The cohort was characterised by clinical-pathological
factors, specifically sex, smoking history, stage (TNM 2018)
and early versus locally advanced (T1/2N0 representing
early disease and T3/4 or node-positive locally advanced;
groupings used to determine current radiotherapy doses
and reflecting the design of the PLATO trial), immunohis-
tochemical staining for p16 and TIL score. Correlation be-
tween factors was investigated using Pearson chi-squared
tests.
A univariate Log-rank analysis to explore prognostic
ability of these clinical and pathological factors was carried
out with respect to the recent international consensus core
outcome set for clinical trials of CRT interventions for anal
cancer (CORMAC) [22]. Specifically, these were disease-free
survival (DFS; defined by time to ASCC recurrence or death),
overall survival and cancer-specific survival (CSS; defined
by time to ASCC death). Outcomes at 2 and 5 years were
described and hazard ratios reported. Survival curves were
generated for DFS, CSS and overall survival by stage, p16 and
TIL status. A multivariate analysis of all clinical pathological
characteristics was carried out using Cox regression. A 5%
significance level was used to declare statistical signifi-
cance. No adjustments were made for multiple testing due
to the hypothesis-generating nature of the research. All
analyses were carried out in STATA.
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Demographics
The cohort of 257 ASCC patients was broadly represen-
tative of previous reports, with a median age of 58 (range
23e96) and a female preponderance (64% cases). De-
mographics for the whole cohort are shown in Table 1.
In total, 29/255 evaluable cases were p16 negative, i.e.
226 or 88.6% patients were p16 positive; 52/251 evaluable
cases showed high levels of TIL, 123/251 scoring moderate
and 76/251 low. p16 staining and TIL scores were inde-
pendent of stage, with similar rates of p16-positive cases in
both early (T1/2N0) and locally advanced (T3/4 or Nþ)
cases. TIL scores were equally distributed between early and
locally advanced tumours (Table 1). TIL groupings were
similarly distributed to previous reports.
Significant correlations were seen between higher T
stage (3/4 versus 1/2) and node positivity. Female patients
were more likely to have higher T-stage tumours (chi-Table 1





























T1/2 N0 (total n ¼ 91) p16-positive 80
p16-negative 11
T3/4 or Nþ(total n ¼ 162) p16-positive 142
p16-negative 18squared coefficient ¼ 4.6, P ¼ 0.033) and male patients
more likely to have tumours that were p16 negative (chi-
squared ¼ 11.9, P ¼ 0.001).Outcomes (Table 2, Figure 1)
DFS and overall survival rates were commensurate
with results from the phase III ACT2 trial [23]. With a
median follow-up of 42.8 months (interquartile range
28.4e62.4), 80/257 patients experienced relapse; the 2-
year DFS was 75.0% (95% confidence interval 69.1e79.9)
falling to 68.7% (95% confidence interval 62.3e74.2) by 5
years. Thirty-six patients relapsed at the primary site
alone and a further 19 patients relapsed locoregionally
(within the pelvis), of whom five had evidence of syn-
chronous metastatic disease. Twenty-five patients pre-
sented with metastatic disease as their first site of
recurrence. This mirrors recently published data charac-
terising ASCC relapses following intensity-modulated
radiotherapy [24]. The CSS for ASCC was 87.6% (95%n %
257


























87.9% TIL 1 27 30.0%
12.1% TIL 2 44 48.9%
TIL 3 21.1%
88.8% TIL 1 47 29.9%
11.2% TIL 2 78 49.7%
TIL 3 20.4%
Table 2
Outcomes (disease-free survival, cancer-specific survival and overall survival) in 257 anal squamous cell carcinomas treated with chemoradiotherapy by sex, stage, p16 status and
tumour infiltrating lymphocyte scores









Univariate Multivariate 2-year (95%
CI)
5-year (95%CI) Univariate Multivariate
































































































































































































































































HR, hazard ratio (95% confidence interval).
*P-value combined across TIL1e3.














Fig 1. Forest plots of hazard ratios (and 95% Confidence Intervals) for univariate and multivariate analysis of prognostic factors in ASCC. a)
Disease Free Survival, b) Cancer Specific Survival, c) Overall Survival.
K. Wakeham et al. / Clinical Oncology 33 (2021) 638e649642confidence interval 82.7e91.1) at 2 years and 78.8% (95%
confidence interval 72.6e83.7) at 5 years (overall 49/257
patients died of anal cancer). For the whole cohort, the
overall survival was 81.6% (95% confidence interval76.2e85.9) at 2 years and 66.3% (95% confidence interval
59.5e72.2) at 5 years; non-ASCC deaths included eight
from second malignancies, nine from cardiovascular dis-
ease and 18 from a range of other causes.
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Figure 2)
Stage, sex, p16 status and TIL score all showed prognostic
value with respect to DFS and overall survival (Log-rank P <
0.05 on univariate analyses) as shown in Table 2 and
Figure 2. Smoking status (recorded in 62% of cases) was not
independently prognostic for outcomes (P ¼ 0.611).
Patients with early stage (T1/2N0) cancers showed a
higher relapse-free rate compared with those with locally
advanced disease (88.7% versus 67.1% at 2 years; hazard ratio
2.69; 95% confidence interval 1.65e4.39). CSS was 97.8% at 2
years in early stage disease and 81.8% in locally advanced
cases (92.5% versus 72.8% at 5 years; hazard ratio 3.24; 95%
confidence interval 1.68e6.27). Two-year overall survival in
patients with locally advanced disease was 75.8% as
compared with 93.3% in T1/2N0 cases; overall survival at 5
yearswas 62.8% versus 75.9%. It is notable that of 23 deaths in
the T1/2 N0 group, only sevenwere as a result of anal cancer.
Male patients had worse DFS than female patients
(hazard ratio 1.62; 95% confidence interval 1.04e2.52). Male
patients also had an increased risk of death (hazard ratio
2.16; 95% confidence interval 1.41e3.32).
Patients with p16-positive tumours had a 2-year relapse-
free rate of 78.2%, as opposed to 49.0% in p16-negative cases
(hazard ratio 2.30; 95% confidence interval 1.26e4.18). The
effect of p16 was of borderline significance with respect to
CSS, but the overall trend was conserved (2-year CSS 89.7%
versus 72.1% in p16 positive versus p16 negative).Fig 2. Outcomes (overall, disease free and cancer specific survival) in 2
histochemistry for p16, b) TIL ¼ tumour infiltrating lymphocytes (1-3) anSignificant differences in overall survival were also
conferred by p16 status (2-year overall survival of 61.7% in
p16-negative cases versus 84.5% when p16 positive).
The 2-year relapse-free rate for differing TIL scores was
84.3%, 75.6% and 69.5% for high, moderate and low TILs,
respectively (hazard ratio 2.53, 95% confidence interval
1.2e5.36 for TIL1 versus TIL3; hazard ratio 1.93, 95% confi-
dence interval 1.94e3.99 for TIL2 versus 3). Again, the effect
on CSS did not reach statistical significance (CSS 92.0%/
89.6%/84.5% in TIL high, moderate and low cases), although
a significant effect on overall survival was seen (2-year
overall survival ranging from 74.7% in TIL low tumours to
86.2% in those scoring TIL high).
Multivariate Analyses of Clinical-Pathological Parameters
In multivariate analysis for DFS using Cox regression,
stage (T and N status), p16 status and TIL score all retained
independent prognostic ability. Advanced stage disease
conferred an increased risk for recurrence with a hazard
ratio of 2.69 (95% confidence interval 1.65e4.39; P ¼ 0.003)
for T3/4 versus T1/2 and 2.55 (95% confidence interval
1.61e4.06; P ¼ 0.001) for node positive versus negative
cases. Male sex was also associated with increased risk of
recurrence (hazard ratio 2.12, 95% confidence interval
1.30e3.44; P ¼ 0.002). Negative staining for p16 showed an
increased risk of recurrence (hazard ratio 2.61; 95% confi-
dence interval 1.37e4.96; P ¼ 0.003), as did lower levels of
TILs (hazard ratio for disease event in TIL1 versus TIL3 2.60,57 ASCC treated with chemoradiotherapy presented by a) immuno-
d c) stage (T1/2 N0 vs T3/4 or Nþ).
K. Wakeham et al. / Clinical Oncology 33 (2021) 638e64964495% confidence interval 1.15e5.82; hazard ratio for TIL2
versus TIL3 2.43, 95% confidence interval 1.11e5.30; P ¼
0.028 for TIL score overall).
In multivariate analysis, death from anal cancer was
higher among individuals with more advanced disease
stage (hazard ratio 2.90, 95% confidence interval 1.41e5.97
for stage T3/4 versus T1/2 and hazard ratio 2.14, 95% con-
fidence interval 1.14e4.03 for node positive versus negative
cases) and among men compared with women (hazard
ratio 2.53, 95% confidence interval 1.36e4.71). Death from
anal cancer was also associated with p16 status (p16
negative as compared with p16 positive, hazard ratio 2.67,
95% confidence interval 1.16e6.15; P¼ 0.021) and for TIL1/2
versus TIL3 (hazard ratio 2.49, 95% confidence interval
0.86e7.21 for TIL2 and 3.62, 95% confidence interval
1.23e10.63 for TIL1; overall P ¼ 0.001.
Corresponding hazard ratios from multivariate analyses
for death from any cause (overall survival) were 2.51 (95%Fig 3. Disease free survival (DFS) in 91 patients with T1/2, N0 ASCC treate
DFS stratified by TIL in those p16þ cases (log rank p¼0.5719).confidence interval 1.36e4.63) for p16 negative versus
positive cases, 2.17 (95% confidence interval 1.34e3.5) for
T3/4 versus T1/2, 2.42 (95% confidence interval 1.52e3.8)
for males versus females and 2.04 (95% confidence interval
0.95e4.38)/3.30 (95% confidence interval 1.52e7.14) for
TIL2/1 versus TIL3 (all P < 0.001).
Pathological Discrimination in Early or Locally Advanced
Disease
In 91 patients with early stage disease (T1/2 N0), p16
status differentiated cases in terms of DFS (hazard ratio
7.58; 95% confidence interval 2.30e24.95; Figure 3a, Log-
rank P  0.001). This cohort of patients had a dispropor-
tionate number of non-anal cancer deaths and relatively
few deaths attributable from anal cancer and as such p16
status was non-discriminatory for overall survival or CSS.
With a small number of events, there was no additionald with chemoRT stratified by a) p16 (log rank p¼0.0001) and then b)
K. Wakeham et al. / Clinical Oncology 33 (2021) 638e649 645prognostic benefit in applying TIL scores to the p16-
positive cases in early disease (Figure 3b, Log-rank p ¼
0.5719).
In locally advanced disease (160 evaluable cases) where
deaths are predominately due to ASCC, p16 status was
prognostic for overall survival (hazard ratio 2.58, 95% con-
fidence interval 1.30e5.13; Figure 4a, Log-rank P ¼ 0.005).
Again, although the trend to improved outcomes in TIL3
patients persisted, with few events, TIL scores did not add
further prognostic information to p16 status (Figure 4b,
Log-rank p ¼ 0.1448).
The independent prognostic ability of TIL scores does
apply to cohorts defined by p16 status. Although by nature
few in number, those p16-negative tumours with high
levels of TIL (10/29 p16-negative tumours in our data) had
100% CSS (Figure 5aec). Among the more numerous p16-Fig 4. Overall survival in 162 T3/4 or Nþ ASCC patients treated with chem
cases (p¼0.1448).positive tumours, TIL scores also conferred a statistically
significant prognostic effect (Log-rank P ¼ 0.026).Discussion
We assembled an independent multicentre cohort of UK
patients with non-metastatic ASCC treated with radical CRT
and investigated clinical-pathological factors with respect
to pertinent outcomes. Key findings are the consistent
prognostic effects of tumour stage (early stage tumours
conferring improved outcomes), p16 status (p16-positive
tumours responding better) and TIL score (high levels of
TILs being associated with improved survival) with respect
to outcomes. The size and multicentre nature of the cohort
allowed us to combine these prognostic factors and identifyoRT stratified by a) p16 (log rank p¼0.0049) and then b) TIL in p16þ
Fig 5. KaplaneMeier curves for p16-negative cohort of anal squamous cell carcinoma (ASCC) patients (n ¼ 29) stratified by tumour infiltrating
lymphocyte (TIL) scores: (a) overall survival for p16-negative cohort of ASCC patients (n ¼ 29) treated with chemoradiotherapy (Log-rank P ¼
0.004); (b) cancer-specific survival for p16-negative cohort of ASCC patients (n ¼ 29) treated with chemoradiotherapy (Log-rank P ¼ 0.007); (c)
disease-free survival for p16-negative cohort of ASCC patients (n ¼ 29) treated with chemoradiotherapy (Log-rank P ¼ 0.038).
K. Wakeham et al. / Clinical Oncology 33 (2021) 638e649646clinically relevant subgroups. Specifically, we have defined
the role for p16 in terms of DFS (although not CSS or overall
survival) in early stage disease, and in the stratification of all
cancer outcomes in locally advanced disease. This finding issupported by recent data from the US National Cancer
Database [25], where using a propensity score matched
analysis, HPV status only conferred a significant benefit for
overall survival in locally advanced cancers.
K. Wakeham et al. / Clinical Oncology 33 (2021) 638e649 647The independent prognostic role for TIL scores shown
here is supported by data from a large Belgian study [26]
and supports host lymphocyte recognition in meditating
outcomes after CRT. Studies comparing the circulating
components of the immune system also support the role of
lymphocytes (as opposed to an inflammatory phenotype) in
mediating outcomes. Leukocytosis (raised white cell count)
is associated with increased risk of relapse [4,15,16]. The
neutrophil:lymphocyte ratio is a strong negative prognostic
factor, where higher neutrophils are associated with a
worse outcome (and higher proportions of lymphocytes a
greater likelihood of cure). The relationship between
circulating immune cells and those within tumours was
demonstrated [27] in a study of 79 patients with ASCC
treated with CRT, where the peripheral blood differential
counts mirrored the intra-tumoural findings. Pretreatment
leukocytosis (total white cell count greater than the me-
dian) was associated with higher stage disease and lower
infiltration of the tumour with CD8þ lymphocytes, which in
itself was associated with an increased risk of relapse. CD8þ
TIL levels were inversely correlated with the amount of
peri-tumoural tumour-associated neutrophils.
To date, although clinical and pathological prognostic
factors have been identified, they are not used to alter
treatment. The highest level evidence for CRT as the stan-
dard of care utilises a defined curative dose of radiotherapy
combined with chemotherapy for all patients. Building on
the prognostic groupings identified here, the next step is to
develop a multivariate prognostic nomogram that can be
prospectively validated across the current generation of
randomised trials in ASCC and assess the predictive role in
novel treatment approaches.
The introduction of intensity-modulated radiotherapy
[28,29] reduces acute toxicity and allows dose escalation
without altering overall treatment time. The PLATO plat-
form (ISRCTN88455282) includes two randomised trials
that test dose alteration and provide the opportunity to
validate prognostic biomarkers and study their predictive
value [30]. ACT4 is a randomised phase II trial comparing
standard versus reduced radiotherapy dose CRT in node-
negative tumours <4 cm. ACT5 is a randomised phase III
trial testing two radiotherapy dose escalation schedules
versus standard dose CRT in locally advanced tumours. In-
tegrated translational work is prospectively analysing tu-
mours for HPV/p16 and TILs enabling, for the first time, an
understanding of the predictive value of these biomarkers
in the context of dose modulation.
HPV-associated cancers seem to have relatively high
response rates to immune checkpoint inhibition [31]; PD1
inhibitors have efficacy in metastatic ASCC [32,33], PD1/
PDL1 is associated with resistance to CRT in head and
neck cancers [34] and phase I/II studies combining im-
mune checkpoint inhibition with CRT are underway in
ASCC, although further studies of disease biology are
important to inform the optimal design. In particular, a
detailed understanding of the interplay between immune
checkpoint inhibition and the pre-existing tumour
microenvironment will be key to patient selection, either
around better determining outcomes following CRT orideally predictive biomarkers of response to immune
checkpoint inhibition.
The data share the limitations of retrospectively
collected series of a relatively rare cancer. Non-cancer
related deaths are frequent, in particular in the cohort of
patients with early stage disease, representing comorbid-
ities and societal factors that are disproportionately asso-
ciated with ASCC. We used p16 as a surrogate for HPV
involvement; it may be that alternative methods yield
subtle differences in prognostic effect. Small numbers make
subgroup analyses challenging, reinforcing the need for
broad collaboration in this area of study and underlining the
importance of prospectively collected PLATO data that will
facilitate validation of p16 and TILs with respect to the range
of pertinent outcomes.
In summary, we have shown the consistent prognostic
effect of p16 immunohistochemistry and TIL scores in a
novel cohort of patients with ASCC treated with CRT. Rates
of p16þ and lymphocyte infiltration appear to be inde-
pendent of tumour stage. Although patients with early tu-
mours appear to do well with CRT, p16-negative cases do
have higher rates of relapse. In locally advanced cases, the
prognostic effect is more clearly seen and impacts on overall
survival. Prospective randomised studies should determine
whether dose escalation or additional therapies improve
outcomes in this high-risk group and investigate a predic-
tive role for these biomarkers in treatment intensification.Conflicts of Interest
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